Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Michael Petter as an independent director to the Company's Board of Directors, effective immediately. Mr. Petter replaces Thomas Baird, who resigned from the Company's Board of Directors effective today, but still remains CEO of the Company.
Michael Petter is an accomplished leader and entrepreneur with significant experience in the psychedelics and cannabis industry, co-founding and acting as a director of several companies that successfully completed M&A transactions. He holds a Bachelors in Computer Science from London University, is a Chartered Engineer and private pilot. Since January 2009, he has been the Managing Director of Eyvo eProcurement Solutions, a US-based private company that is a leading eProcurement provider in the SaaS space. He also runs a business mentoring program that assists businesses and individuals with change management.
Mr. Petter has significant psychedelic and cannabis industry expertise. Mike was co-founder and director of Eleusian Biosciences Corp., which the Company acquired in July 2020. He also co-founded and was a director of Tassili Life Sciences Corp. which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Petter has independent board experience being chairman of a compensation committee and as a member of an audit committee. His executive advisory skills focus on providing guidance on strategy, operations, finance and logistics.
Jonathan Gilbert, Executive Chairman of Lobe states, "We are extremely pleased to have Mike join our team with his extensive leadership and industry expertise. I have had the privilege of working with him co-founding several companies including Tassili and Eleusian. Michael is a successful businessman and his experience as a seasoned board member in our industry will be extremely valuable to the Company as we continue to drive innovation, and strive to be a leader in this exciting and emerging industry."
The Company would also like to thank Mr. Baird for his contributions to the Board of Directors.
About Lobe Sciences Ltd.
Lobe is a growth-oriented research, technology & services company that provides financial, management, IP and branding support to businesses. The Company operates a portfolio of companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, Lobe Sciences creates value through acquisitions and development of assets, products and technologies by leveraging its scientific, engineering, branding and operational expertise supported by strong capital markets acumen.
For further information please contact:
Lobe Sciences Ltd.
Jonathan Gilbert
Executive Chairman
info@lobesciences.com
Tel: (949) 505-5623
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Disclaimer for Forward-Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.
Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products
Released On: 5/19/2021
Views: 908
Lobe Sciences to Present at the Benzinga Global Small Cap Conference
Released On: 5/6/2021
Views: 855
Lobe Sciences Acquires Vitamind Line of Wellness Products
Released On: 5/4/2021
Views: 810
Lobe Sciences Announces Filing of PCT Application
Released On: 4/29/2021
Views: 774
Lobe Sciences Retains Jolt Communications to Increase Investor Awareness
Released On: 2/12/2021
Views: 1080
Meet Lobe Sciences A Life Sciences Company Focused on Psychedelic Medicines
Released On: 2/8/2021
Views: 1390
Lobe Sciences Announces Pending Patents and Preclinical Research Studies
Released On: 2/5/2021
Views: 1016
Lobe Sciences Announces Management Changes and New Director
Released On: 1/18/2021
Views: 931
Lobe Sciences Announces Changes to Board of Directors
Released On: 1/8/2021
Views: 897
Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors
Released On: 12/14/2020
Views: 895
Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.
Released On: 12/1/2020
Views: 808
Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine
Released On: 11/30/2020
Views: 809